Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The N-methyl-D-aspartate (NMDA) receptor is a heterotetrameric ligand-gated ion channel essential for excitatory neurotransmission and synaptic plasticity in the central nervous system (StatPearls, 2023). Subtypes containing the GluN2B subunit, encoded by the GRIN2B gene, are primarily expressed in the forebrain and are critical regulators of calcium influx, which is vital for long-term potentiation and memory formation (UniProt, Q13224). Dysregulation of GluN2B-containing receptors is heavily implicated in the pathophysiology of major depressive disorder, chronic pain, and neurodegenerative diseases like Alzheimer's, often due to glutamate-mediated excitotoxicity (PubMed, PMID: 30107114). Pharmacological targeting of these specific subtypes, particularly through negative allosteric modulators (NAMs), aims to provide therapeutic benefits such as rapid antidepressant effects while minimizing the severe dissociative side effects associated with non-selective NMDA antagonists like ketamine (PubMed, PMID: 25563902). These drugs typically bind to the interface of the GluN1 and GluN2B subunits, reducing the channel's open probability in a state-dependent manner to normalize glutamatergic signaling.
Negative allosteric modulation of the GluN2B subunit to inhibit ion channel activity and reduce calcium influx; non-competitive antagonism.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on N-methyl-D-aspartate receptor subunit 2B (GluN2B) (GluN2B).